Latest News

  • Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference Read More
  • Alkermes Media Statement Regarding FDA Warning Letter Read More

Investors

Working at Alkermes